Revance to Participate in the Needham 22nd Annual Healthcare Conference

Rhea-AI Summary

Revance Therapeutics, Inc. (NASDAQ: RVNC) will participate in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. CFO Tobin Schilke is set to engage in a fireside chat on April 18 at 12:45 PM ET. The conference's live audio webcast can be accessed via the company's Investor Relations page, with a replay available for 90 days post-event. Revance focuses on innovative aesthetic and therapeutic solutions, including the DAXXIFY® injection for muscle movement disorders. Headquartered in Nashville, Tennessee, Revance also operates in Newark, Pleasanton, and Irvine, California.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that the company will participate in the 22^nd Annual Needham Virtual Healthcare Conference, taking place April 17 – 20, 2023. Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, April 18, at 12:45 P.M. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity.

Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on LinkedIn.

“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230405005155/en/

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

sfahy@revance.com

Source: Revance Therapeutics, Inc.

FAQ

When is Revance Therapeutics participating in the Needham Virtual Healthcare Conference?

Revance Therapeutics will participate in the Needham Virtual Healthcare Conference from April 17 to April 20, 2023.

Who will represent Revance at the Needham Virtual Healthcare Conference?

CFO Tobin Schilke will represent Revance Therapeutics during a fireside chat on April 18, 2023, at 12:45 PM ET.

How can I access the Revance Therapeutics conference webcast?

The live audio webcast can be accessed from the Investor Relations section of Revance's website.

What is DAXXIFY® offered by Revance Therapeutics?

DAXXIFY® is an injection developed by Revance for treating muscle movement disorders.

Where is Revance Therapeutics headquartered?

Revance Therapeutics is headquartered in Nashville, Tennessee.